Based on this revised guidance, GAAP net income is expected to be in the range of $12 to $17 million. Adjusted cash net income, which adds back the after tax impact of book amortization of intangible assets, the amortization and write off of deferred financing costs and the expenses associated with litigation settlements through the nine months ended September 30, 2007, is expected to be in the range of $258 to $263 million. Using 250.6 million Class A common shares, the Company expects adjusted cash net income per share to be in the range of $1.03 to $1.05 for the full year 2007.
For a detailed view of the Company's 2007 financial guidance please refer to the summary at the end of this press release.
Investor Conference Call
The Company is hosting a conference call, open to all interested parties, on Friday, November 9, 2007 beginning at 8:00 AM EST. The number to call within the United States and Canada is (888) 503-8171. Participants outside the United States and Canada should call (719) 325-2288. The conference ID number is 4883748. A replay of the conference call will be available from two hours after the call through midnight EST on December 7, 2007 and can be accessed by dialing (888) 203-1112 from within the United States and Canada or (719) 457-0820 from outside the United States and Canada.
The Company
Warner Chilcott is a leading specialty pharmaceutical company focused
on developing, manufacturing, marketing and selling branded prescription
products in the women's healthcare and dermatology th
'/>"/>
| SOURCE Warner Chilcott Limited Copyright©2007 PR Newswire. All rights reserved |